Ad is loading...
BNGO
Price
$0.25
Change
-$0.01 (-3.85%)
Updated
Nov 15 closing price
CERS
Price
$1.72
Change
-$0.08 (-4.44%)
Updated
Nov 15 closing price
95 days until earnings call
Ad is loading...

BNGO vs CERS

Header iconBNGO vs CERS Comparison
Open Charts BNGO vs CERSBanner chart's image
Bionano Genomics
Price$0.25
Change-$0.01 (-3.85%)
Volume$2.84M
CapitalizationN/A
Cerus
Price$1.72
Change-$0.08 (-4.44%)
Volume$1.5M
CapitalizationN/A
BNGO vs CERS Comparison Chart
Loading...
BNGO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
CERS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
BNGO vs. CERS commentary
Nov 17, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BNGO is a Sell and CERS is a StrongSell.

COMPARISON
Comparison
Nov 17, 2024
Stock price -- (BNGO: $0.25 vs. CERS: $1.72)
Brand notoriety: BNGO and CERS are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: BNGO: 115% vs. CERS: 91%
Market capitalization -- BNGO: $57.43M vs. CERS: $342.62M
BNGO [@Medical Specialties] is valued at $57.43M. CERS’s [@Medical Specialties] market capitalization is $342.62M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BNGO’s FA Score shows that 1 FA rating(s) are green whileCERS’s FA Score has 0 green FA rating(s).

  • BNGO’s FA Score: 1 green, 4 red.
  • CERS’s FA Score: 0 green, 5 red.
According to our system of comparison, both BNGO and CERS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BNGO’s TA Score shows that 5 TA indicator(s) are bullish while CERS’s TA Score has 5 bullish TA indicator(s).

  • BNGO’s TA Score: 5 bullish, 3 bearish.
  • CERS’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, BNGO is a better buy in the short-term than CERS.

Price Growth

BNGO (@Medical Specialties) experienced а -11.82% price change this week, while CERS (@Medical Specialties) price change was -3.37% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.23%. For the same industry, the average monthly price growth was -2.87%, and the average quarterly price growth was -6.14%.

Reported Earning Dates

BNGO is expected to report earnings on Nov 09, 2023.

CERS is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Medical Specialties (-4.23% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CERS($343M) has a higher market cap than BNGO($57.4M). CERS YTD gains are higher at: -20.370 vs. BNGO (-86.979). CERS has higher annual earnings (EBITDA): -26.34M vs. BNGO (-213.4M). BNGO has more cash in the bank: 102M vs. CERS (65.9M). BNGO has less debt than CERS: BNGO (79.4M) vs CERS (96M). CERS has higher revenues than BNGO: CERS (156M) vs BNGO (36.1M).
BNGOCERSBNGO / CERS
Capitalization57.4M343M17%
EBITDA-213.4M-26.34M810%
Gain YTD-86.979-20.370427%
P/E RatioN/AN/A-
Revenue36.1M156M23%
Total Cash102M65.9M155%
Total Debt79.4M96M83%
FUNDAMENTALS RATINGS
BNGO vs CERS: Fundamental Ratings
BNGO
CERS
OUTLOOK RATING
1..100
6217
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9795
PRICE GROWTH RATING
1..100
9676
P/E GROWTH RATING
1..100
91100
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BNGO's Valuation (27) in the Biotechnology industry is in the same range as CERS (50) in the Medical Specialties industry. This means that BNGO’s stock grew similarly to CERS’s over the last 12 months.

BNGO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CERS (100) in the Medical Specialties industry. This means that BNGO’s stock grew similarly to CERS’s over the last 12 months.

CERS's SMR Rating (95) in the Medical Specialties industry is in the same range as BNGO (97) in the Biotechnology industry. This means that CERS’s stock grew similarly to BNGO’s over the last 12 months.

CERS's Price Growth Rating (76) in the Medical Specialties industry is in the same range as BNGO (96) in the Biotechnology industry. This means that CERS’s stock grew similarly to BNGO’s over the last 12 months.

BNGO's P/E Growth Rating (91) in the Biotechnology industry is in the same range as CERS (100) in the Medical Specialties industry. This means that BNGO’s stock grew similarly to CERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BNGOCERS
RSI
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
72%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
79%
MACD
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 12 days ago
79%
Bullish Trend 7 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 7 days ago
82%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
79%
View a ticker or compare two or three
Ad is loading...
BNGO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
CERS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EEIFX10.67-0.07
-0.65%
Monteagle Enhanced Equity Income Instl
FIIMX26.17-0.29
-1.10%
Fidelity Advisor Mid Cap II I
ITHIX47.53-0.66
-1.37%
Hartford Capital Appreciation I
EGOIX19.97-0.33
-1.63%
Allspring Large Cap Core Inst
JTKNX14.27-0.24
-1.65%
JHancock Global Thematic Opps NAV

CERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CERS has been loosely correlated with MASS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then MASS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERS
1D Price
Change %
CERS100%
-4.44%
MASS - CERS
50%
Loosely correlated
+0.42%
FLGT - CERS
45%
Loosely correlated
-2.70%
BNGO - CERS
43%
Loosely correlated
-3.83%
BLFS - CERS
42%
Loosely correlated
-2.91%
CRL - CERS
42%
Loosely correlated
-4.65%
More